All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

alimemazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	2749	84-96-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: alimemazine alimemazine tartrate temaril trimeprazine tartrate trimeprazine alimezine methylpromazine teralene	A phenothiazine derivative that is used as an antipruritic. Molecular weight: 298.45 Formula: C18H22N2S CLOGP: 5 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 6.48 ALOGS: -4.55 ROTB: 4 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O
30	mg	P

ADMET properties:

Property	Value	Reference
S (Water solubility)	100 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	2.980		Moderate	0.74
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.388		Moderate	0.74
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	29.512	10^-6 cm/s	Moderate	0.74
dh-clint	Dog hepatocyte intrinsic clearance	79.250	uL/min/10^6 cells	Moderate	0.74
dppb	Dog plasma protein binding (% unbound)	3.500	%	Moderate	0.74
fcs-ppb	Fetal calf serum protein binding (% unbound)	10.800	%	Moderate	0.74
herg	hERG pIC50	5.974	pIC50	Moderate	0.74
hh-clint	Human hepatocyte intrinsic clearance	11.885	uL/min/10^6 cells	Moderate	0.74
hlm-clint	Human liver microsomal intrinsic clearance	31.769	uL/min/mg protein	Moderate	0.74
hppb	Human plasma protein binding (% unbound)	5.050	%	Moderate	0.74
kinase-safety-class	ACVR2B,AKT2,AXL,BRAF,CAMK2B,CAMK2D,CDK4,CDK5,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK12,MET,NTRK2,PDK2,PDK4,PDPK1,PIM2,PRKDC,TEK	26
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	0.437		Moderate	0.74
mh-clint	Mouse hepatocyte intrinsic clearance	174.582		Moderate	0.74
mppb	Mouse plasma protein binding (% unbound)	7.080		Moderate	0.74
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	2.355		Moderate	0.74
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	1		Moderate	0.67
pppb	Pig plasma protein binding (% unbound)	16.220	%	Moderate	0.74
rh-clint	Rat hepatocyte intrinsic clearance	220.800	uL/min/10^6 cells	Moderate	0.74
rh-fuinc	Rat hepatocyte fraction unbound in incubation	35.410	%	Moderate	0.74
rppb	Rat plasma protein binding (% unbound)	6.370	%	Moderate	0.74
solubility-dd	Solubility at pH 7.4 in DMSO	533.335	uM	Moderate	0.74

Approvals:

Date	Agency	Company	Orphan
None	FDA	ALLERGAN HERBERT

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intentional overdose	1513.46	51.39	480	7161	93354	90527452
Intentional self-injury	1494.42	51.39	370	7271	28964	90591842
Coma	778.34	51.39	274	7367	72358	90548448
Poisoning deliberate	767.92	51.39	194	7447	16292	90604514
Somnolence	325.38	51.39	208	7433	208876	90411930
Toxicity to various agents	278.49	51.39	214	7427	287632	90333174
Suicide attempt	245.68	51.39	122	7519	75277	90545529
Tachycardia	218.32	51.39	146	7495	157527	90463279
Depressed level of consciousness	199.95	51.39	105	7536	72679	90548127
Bradypnoea	197.75	51.39	51	7590	4607	90616199
Electrocardiogram QT prolonged	191.87	51.39	102	7539	72354	90548452
Altered state of consciousness	145.69	51.39	65	7576	31467	90589339
Cardio-respiratory arrest	129.05	51.39	75	7566	63065	90557741
Substance use disorder	125.37	51.39	30	7611	1990	90618816
Rhabdomyolysis	121.23	51.39	67	7574	51189	90569617
Poisoning	120.07	51.39	46	7595	15171	90605635
Drug use disorder	118.40	51.39	39	7602	8304	90612502
Drug abuse	117.96	51.39	78	7563	82269	90538537
Hypotension	114.81	51.39	139	7502	325258	90295548
Hepatocellular injury	109.65	51.39	52	7589	28906	90591900
Hepatic cytolysis	109.42	51.39	53	7588	30863	90589943
Mydriasis	106.46	51.39	42	7599	14970	90605836
Hypothermia	101.50	51.39	41	7600	15534	90605272
Miosis	98.14	51.39	35	7606	9449	90611357
Akathisia	85.41	51.39	33	7608	11126	90609680
Drug reaction with eosinophilia and systemic symptoms	85.23	51.39	50	7591	42708	90578098
Bladder dilatation	83.76	51.39	19	7622	996	90619810
Drug dependence	76.71	51.39	41	7600	29286	90591520
Pneumonia aspiration	76.70	51.39	46	7595	40894	90579912
Cholestasis	76.46	51.39	44	7597	36255	90584551
Hyperthermia	66.62	51.39	27	7614	10308	90610498
Pyramidal tract syndrome	65.78	51.39	14	7627	545	90620261
Extrapyramidal disorder	63.92	51.39	30	7611	16273	90604533
Suicidal ideation	60.51	51.39	50	7591	73805	90547001
Serotonin syndrome	56.90	51.39	37	7604	37850	90582956
Hypercapnic coma	56.90	51.39	11	7630	262	90620544
Faecaloma	56.27	51.39	24	7617	10407	90610399
Asphyxia	54.33	51.39	21	7620	7082	90613724
Arthralgia	53.64	51.39	3	7638	778519	89842287
Pain	53.08	51.39	10	7631	996331	89624475

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	949.59	37.99	329	5320	53225	42562461
Poisoning deliberate	354.99	37.99	105	5544	10029	42605657
Intentional self-injury	258.46	37.99	91	5558	15111	42600575
Intentional overdose	255.45	37.99	128	5521	51328	42564358
Drug abuse	232.18	37.99	154	5495	104617	42511069
Miosis	192.83	37.99	71	5578	13375	42602311
Toxicity to various agents	179.97	37.99	184	5465	228952	42386734
Somnolence	172.11	37.99	145	5504	140960	42474726
Drug use disorder	168.47	37.99	60	5589	10273	42605413
Substance use disorder	163.76	37.99	50	5599	5295	42610391
Poisoning	130.92	37.99	55	5594	14644	42601042
Altered state of consciousness	81.90	37.99	50	5599	29209	42586477
Electrocardiogram QT prolonged	74.63	37.99	57	5592	47888	42567798
Pneumonia aspiration	74.60	37.99	58	5591	50020	42565666
Tachycardia	73.18	37.99	78	5571	101009	42514677
Extrapyramidal disorder	64.51	37.99	35	5614	16377	42599309
Depressed level of consciousness	63.82	37.99	52	5597	47918	42567768
Suicide attempt	61.39	37.99	50	5599	46050	42569636
Pulmonary oedema	57.07	37.99	51	5598	53221	42562465
Hepatocellular injury	52.64	37.99	35	5614	23643	42592043
Rhabdomyolysis	50.83	37.99	57	5592	77962	42537724
Cardio-respiratory arrest	47.31	37.99	48	5601	58588	42557098
Mydriasis	46.86	37.99	23	5626	8747	42606939
Intestinal obstruction	46.03	37.99	34	5615	27124	42588562
Drug ineffective	44.95	37.99	14	5635	630183	41985503
Faecaloma	44.48	37.99	20	5629	6250	42609436
Bradypnoea	44.37	37.99	18	5631	4375	42611311
Drug dependence	43.95	37.99	34	5615	29060	42586626
Tongue biting	41.23	37.99	12	5637	1075	42614611
Substance abuse	40.67	37.99	21	5628	8884	42606802
Catatonia	38.30	37.99	18	5631	6221	42609465

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	1696.75	37.68	595	11817	117274	110459613
Poisoning deliberate	1120.53	37.68	306	12106	26025	110550862
Intentional overdose	1082.95	37.68	443	11969	132058	110444829
Intentional self-injury	1061.76	37.68	317	12095	37112	110539775
Somnolence	502.80	37.68	347	12065	297102	110279785
Toxicity to various agents	442.12	37.68	391	12021	480164	110096723
Drug abuse	320.41	37.68	216	12196	177195	110399692
Miosis	295.50	37.68	106	12306	21877	110555010
Drug use disorder	288.30	37.68	99	12313	17975	110558912
Substance use disorder	287.69	37.68	80	12332	7210	110569677
Suicide attempt	261.81	37.68	156	12256	103238	110473649
Electrocardiogram QT prolonged	254.25	37.68	156	12256	108804	110468083
Tachycardia	253.75	37.68	207	12205	226438	110350449
Poisoning	245.79	37.68	100	12312	29005	110547882
Altered state of consciousness	222.93	37.68	115	12297	57511	110519376
Bradypnoea	217.85	37.68	67	12345	8582	110568305
Depressed level of consciousness	177.23	37.68	126	12286	112152	110464735
Rhabdomyolysis	162.65	37.68	123	12289	120278	110456609
Cardio-respiratory arrest	162.40	37.68	121	12291	115715	110461172
Pneumonia aspiration	158.64	37.68	104	12308	81129	110495758
Hepatocellular injury	156.31	37.68	87	12325	50555	110526332
Mydriasis	140.03	37.68	62	12350	22095	110554792
Extrapyramidal disorder	127.34	37.68	63	12349	28804	110548083
Hypothermia	126.82	37.68	61	12351	26241	110550646
Hepatic cytolysis	116.10	37.68	74	12338	54979	110521908
Drug dependence	102.41	37.68	66	12346	49954	110526933
Faecaloma	101.60	37.68	44	12368	14864	110562023
Bladder dilatation	97.27	37.68	27	12385	2412	110574475
Hypotension	94.74	37.68	192	12220	523657	110053230
Asphyxia	84.13	37.68	38	12374	14177	110562710
Drug ineffective	77.82	37.68	37	12375	1520503	109056384
Akathisia	74.43	37.68	37	12375	17076	110559811
Pain	73.84	37.68	10	12402	954945	109621942
Drug reaction with eosinophilia and systemic symptoms	71.33	37.68	65	12347	82030	110494857
Hyperthermia	66.84	37.68	37	12375	21235	110555652
Intestinal obstruction	64.42	37.68	51	12361	53176	110523711
Arthralgia	63.08	37.68	7	12405	779625	109797262
Regurgitation	63.06	37.68	21	12391	3464	110573423
Sinus tachycardia	61.20	37.68	46	12366	44447	110532440
Substance abuse	60.35	37.68	29	12383	12434	110564453
Drug interaction	59.98	37.68	156	12256	500027	110076860
Cholestasis	59.82	37.68	53	12359	64465	110512422
Serotonin syndrome	59.70	37.68	51	12361	59102	110517785
Disturbance in attention	59.63	37.68	52	12360	61943	110514944
Hypercapnic coma	57.47	37.68	13	12399	502	110576385
Suicidal ideation	56.73	37.68	61	12351	93876	110483011
Pyramidal tract syndrome	56.00	37.68	14	12398	833	110576054
Bradycardia	54.88	37.68	77	12335	155440	110421447
Haemodynamic instability	53.86	37.68	33	12379	22855	110554032
Overdose	53.66	37.68	95	12317	233699	110343188
Hyponatraemia	51.97	37.68	90	12322	217563	110359324
Pneumonia	51.82	37.68	17	12395	876697	109700190
Diarrhoea	50.55	37.68	33	12379	1139472	109437415
Choking	46.70	37.68	26	12386	15084	110561803
Neuroleptic malignant syndrome	46.37	37.68	35	12377	34024	110542863
Thymus disorder	45.39	37.68	11	12401	575	110576312
Rash maculo-papular	42.71	37.68	47	12365	74175	110502712
Morbid thoughts	40.47	37.68	11	12401	908	110575979
Victim of crime	40.34	37.68	12	12400	1371	110575516
Catatonia	39.23	37.68	21	12391	11279	110565608
Lipase increased	39.09	37.68	25	12387	18647	110558240
Hepatitis acute	38.98	37.68	25	12387	18741	110558146
Pulmonary oedema	38.75	37.68	52	12360	100607	110476280
Myoclonus	38.60	37.68	31	12381	32967	110543920
Intentional product misuse	38.51	37.68	60	12352	132844	110444043

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R06AD01	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Phenothiazine derivatives
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018494	Histamine Agents
MeSH PA	D000982	Antipruritics
MeSH PA	D003879	Dermatologic Agents

Related Drugs by ATC class:

R06AD Phenothiazine derivatives 8 drugs

hydroxyethylpromethazineisothipendylmequitazinemethdilazineoxomemazinepromethazinethiazinamthiethylperazine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Dermatographic urticaria	indication	7632005	DOID:743
Angioedema	indication	41291007	DOID:1558
General anesthesia	indication	50697003
Allergic rhinitis	indication	61582004
Nasal discharge	indication	64531003
Nasal congestion	indication	68235000
Sneezing	indication	76067001
Urticaria	indication	126485001
Itching of skin	indication	418363000
Allergic conjunctivitis	indication	473460002	DOID:11204
Alcoholism	contraindication	7200002
Organophosphate poisoning	contraindication	8260003
Weight gain finding	contraindication	8943002
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Chronic disease of respiratory system	contraindication	17097001
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Orthostatic hypotension	contraindication	28651003
Torsades de pointes	contraindication	31722008
Parkinsonism	contraindication	32798002
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Extrapyramidal disease	contraindication	76349003
Hyperglycemia	contraindication	80394007	DOID:4195
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Stupor	contraindication	89458003
Tardive dyskinesia	contraindication	102449007
Prolonged QT interval	contraindication	111975006
Acute disease of cardiovascular system	contraindication	128487001
Angina pectoris	contraindication	194828000
Disease of liver	contraindication	235856003	DOID:409
Metabolic syndrome X	contraindication	237602007	DOID:14221
Hyperprolactinemia	contraindication	237662005	DOID:12700
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Anemia	contraindication	271737000	DOID:2355
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Coma	contraindication	371632003
At risk for aspiration	contraindication	371736008
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Congenital long QT syndrome	contraindication	442917000
Carcinoma of female breast	contraindication	447782002

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Itching	Indication
Dogs	Inflammation	Indication
Dogs	Adjunctive therapy in various cough conditions	Indication
Dogs	Acute or chronic bacterial infections provided the infection is controlled by appropriate antibiotic or chemotherapeutic agents	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Temaril-P Tablets	Zoetis Inc.	2
Temaril-P Spansule Capsule No. 1, Temaril-P Spansule Capsule No. 2	Zoetis Inc.	2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.92	Basic
pKa2	3.55	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST				CHEMBL	CHEMBL
FAD-linked sulfhydryl oxidase ALR	Enzyme	P55789	ALR_HUMAN		AC50	5.90		CHEMBL

External reference:

ID	Source
4019960	VUID
N0000148045	NUI
D02245	KEGG_DRUG
4330-99-8	SECONDARY_CAS_RN
4018016	VANDF
4019960	VANDF
C0041031	UMLSCUI
CHEBI:9725	CHEBI
CHEMBL829	ChEMBL_ID
5574	PUBCHEM_CID
DB01246	DRUGBANK_ID
CHEMBL3989885	ChEMBL_ID
7237	IUPHAR_LIGAND_ID
C031242	MESH_SUPPLEMENTAL_RECORD_UI
10825	RXNORM
2318	MMSL
5629	MMSL
d00788	MMSL
001535	NDDF
001536	NDDF
387471006	SNOMEDCT_US
52803004	SNOMEDCT_US
8109005	SNOMEDCT_US
D014291	MESH_DESCRIPTOR_UI
706	INN_ID
362NW1LD6Z	UNII
362NW1LD6Z	INXIGHT DRUGS

Pharmaceutical products:

None